Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals - Endpoints News

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News

February 18, 2026

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways stock soars after positive Phase 3 trial results By Investing.com Investing.com AustraliaCMPS: COMP360 showed rapid, durable efficacy and strong safety in TRD, with launch preparations underway TradingView